Execs expect study to expand market for implantable heart devices

06/15/2009 | Reuters

Medical-device executives are optimistic that the market for cardiac resynchronization therapy devices and other expensive implants could double if the MADIT-CRT study yields positive results. The Boston Scientific-sponsored study aims to show that combining defibrillators with CRT devices could delay the progression of early-stage heart failure. An analyst with FAF Advisors, however, said reimbursement will play a key role in boosting the sales of the combination products.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX